Dermata Therapeutics Net Income
| DRMA Stock | USD 1.82 0.05 2.82% |
As of the 6th of February, Dermata Therapeutics shows the Standard Deviation of 9.81, variance of 96.3, and Mean Deviation of 6.69. Dermata Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Dermata Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Dermata Therapeutics' valuation are provided below:We have found one hundred available fundamental signals for Dermata Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Dermata Therapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -11.1 M | -11.6 M | |
| Net Loss | -8.6 M | -9.1 M | |
| Net Loss | -11.1 M | -11.6 M | |
| Net Loss | (72.28) | (75.89) |
Dermata | Net Income | Build AI portfolio with Dermata Stock |
Analyzing Dermata Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Dermata Therapeutics's current valuation and future prospects.
Latest Dermata Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Dermata Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Dermata Therapeutics financial statement analysis. It represents the amount of money remaining after all of Dermata Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Dermata Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dermata Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (12.29 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Dermata Net Income Regression Statistics
| Arithmetic Mean | (6,515,407) | |
| Coefficient Of Variation | (44.77) | |
| Mean Deviation | 2,496,399 | |
| Median | (4,721,356) | |
| Standard Deviation | 2,916,968 | |
| Sample Variance | 8.5T | |
| Range | 9.1M | |
| R-Value | (0.79) | |
| Mean Square Error | 3.4T | |
| R-Squared | 0.63 | |
| Significance | 0.0002 | |
| Slope | (457,151) | |
| Total Sum of Squares | 136.1T |
Dermata Net Income History
Other Fundumenentals of Dermata Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Dermata Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Dermata Therapeutics is extremely important. It helps to project a fair market value of Dermata Stock properly, considering its historical fundamentals such as Net Income. Since Dermata Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dermata Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dermata Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. Projected growth potential of Dermata fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Dermata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Dermata Therapeutics's market price often diverges from its book value, the accounting figure shown on Dermata's balance sheet. Smart investors calculate Dermata Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Dermata Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Dermata Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dermata Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Dermata Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Dermata Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Dermata Therapeutics.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Dermata Therapeutics on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Dermata Therapeutics or generate 0.0% return on investment in Dermata Therapeutics over 90 days. Dermata Therapeutics is related to or competes with Avenue Therapeutics, Psyence Biomedical, Lipella Pharmaceuticals, Virax Biolabs, Elevai Labs, GT Biopharma, and Revelation Biosciences. Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializ... More
Dermata Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Dermata Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Dermata Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 61.86 | |||
| Value At Risk | (16.23) | |||
| Potential Upside | 16.18 |
Dermata Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dermata Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Dermata Therapeutics' standard deviation. In reality, there are many statistical measures that can use Dermata Therapeutics historical prices to predict the future Dermata Therapeutics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (1.01) | |||
| Treynor Ratio | (0.17) |
Dermata Therapeutics February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 6.69 | |||
| Coefficient Of Variation | (1,806) | |||
| Standard Deviation | 9.81 | |||
| Variance | 96.3 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (1.01) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 61.86 | |||
| Value At Risk | (16.23) | |||
| Potential Upside | 16.18 | |||
| Skewness | 1.31 | |||
| Kurtosis | 4.85 |
Dermata Therapeutics Backtested Returns
Dermata Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0509, which denotes the company had a -0.0509 % return per unit of risk over the last 3 months. Dermata Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Dermata Therapeutics' Variance of 96.3, mean deviation of 6.69, and Standard Deviation of 9.81 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.18, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Dermata Therapeutics will likely underperform. At this point, Dermata Therapeutics has a negative expected return of -0.52%. Please make sure to confirm Dermata Therapeutics' kurtosis, and the relationship between the value at risk and rate of daily change , to decide if Dermata Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.16 |
Very weak predictability
Dermata Therapeutics has very weak predictability. Overlapping area represents the amount of predictability between Dermata Therapeutics time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Dermata Therapeutics price movement. The serial correlation of 0.16 indicates that over 16.0% of current Dermata Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.16 | |
| Spearman Rank Test | 0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Dermata Therapeutics reported net income of (12.29 Million). This is 103.6% lower than that of the Biotechnology sector and 117.54% lower than that of the Health Care industry. The net income for all United States stocks is 102.15% higher than that of the company.
Dermata Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dermata Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics of similar companies.Dermata Therapeutics is currently under evaluation in net income category among its peers.
Dermata Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Dermata Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Dermata Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dermata Therapeutics' value.| Shares | Ubs Group Ag | 2025-06-30 | 91 K | Geode Capital Management, Llc | 2025-06-30 | 27.4 K | Jones Financial Companies Lllp | 2025-06-30 | 12 K | Tower Research Capital Llc | 2025-06-30 | 5.3 K | Sbi Securities Co Ltd | 2025-06-30 | 1 K | Bank Of America Corp | 2025-06-30 | 31.0 | Wells Fargo & Co | 2025-06-30 | 0.0 | Armistice Capital, Llc | 2025-06-30 | 0.0 |
Dermata Fundamentals
| Return On Equity | -2.03 | ||||
| Return On Asset | -0.96 | ||||
| Current Valuation | 1.06 M | ||||
| Shares Outstanding | 3.2 M | ||||
| Shares Owned By Insiders | 45.17 % | ||||
| Shares Owned By Institutions | 11.77 % | ||||
| Number Of Shares Shorted | 319.01 K | ||||
| Price To Book | 1.32 X | ||||
| EBITDA | (12.29 M) | ||||
| Net Income | (12.29 M) | ||||
| Cash And Equivalents | 10.63 M | ||||
| Cash Per Share | 1.05 X | ||||
| Total Debt | 1.97 M | ||||
| Current Ratio | 8.07 X | ||||
| Book Value Per Share | 4.69 X | ||||
| Cash Flow From Operations | (11.16 M) | ||||
| Short Ratio | 0.14 X | ||||
| Earnings Per Share | 15.99 X | ||||
| Target Price | 10.0 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 6.17 M | ||||
| Total Asset | 3.53 M | ||||
| Retained Earnings | (65.68 M) | ||||
| Working Capital | 1.56 M | ||||
| Net Asset | 3.53 M |
About Dermata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:Check out For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. Projected growth potential of Dermata fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Dermata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Dermata Therapeutics's market price often diverges from its book value, the accounting figure shown on Dermata's balance sheet. Smart investors calculate Dermata Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Dermata Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Dermata Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dermata Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.